Mathematical Models of Topically and Intravitreally Applied Ranibizumab
Investigative Ophthalmology & Visual Science · 2025
DOI: 10.1167/iovs.66.11.45 ↗At a glance
Journal article in Investigative Ophthalmology & Visual Science, 2025. Written by Paul A Roberts and 6 co-authors. Institution: Centre for Systems Modelling and Quantitative Biomedicine, University of Birmingham, Birmingham, United Kingdom. Major MEDLINE topics: Angiogenesis Inhibitors, Vitreous Body, Models, Theoretical. 108 references. The full text is freely available (open access, CC BY 4.0).
Abstract (original language)
Purpose
Wet age-related macular degeneration (AMD) causes vision loss when vascular endothelial growth factor (VEGF) stimulates blood vessel growth into the light-sensitive retina. Anti-VEGF treatments such as ranibizumab are currently administered to treat wet AMD via intravitreal injections, which are unpleasant, expensive, and risk complications. We explored the efficacy of topically administered ranibizumab, with cell-penetrating peptides (CPPs).
Methods
Ex vivo pig eyes were divided into three groups and treated with (1) topical or (2) intravitreal ranibizumab and CPP, or (3) intravitreal ranibizumab. ELISAs measured ranibizumab and VEGF concentrations in the aqueous and vitreous at 20 min, 40 min, 1 h, and 3.5 h (n = 3, per group). An ordinary differential equation model was formulated to describe the evolving concentrations of ranibizumab, VEGF, and their compounds in the tear, aqueous, and vitreal compartments.
Results
Experimental-Topical: aqueous ranibizumab levels increased significantly, coincident with a significant drop in aqueous VEGF. Vitreal ranibizumab increased significantly, while vitreal VEGF remained constant. Intravitreal (with and without CPP): vitreal ranibizumab reached high concentrations, coincident with a significant drop in vitreal VEGF. Mathematical-topical treatment may provide sustained, moderate suppression of vitreal VEGF levels, while intravitreal treatment provides strong suppression, which lessens between treatments.
Conclusions
CPP allows topical ranibizumab to penetrate the cornea. Combined intravitreal/topical treatment presents a promising approach; topical treatment suppresses vitreal VEGF levels between injections and thereby potentially reduces the frequency of injections. Treatment efficacy would be enhanced if ranibizumab's rate of binding to VEGF or tear residence time could be increased.
Subjects
MeSH terms (MEDLINE)
Substances
Authors and institutions
- Centre for Systems Modelling and Quantitative Biomedicine, University of Birmingham, Birmingham, United Kingdom.
- Department of Optometry and Visual Sciences, City St George's, University of London, London, United Kingdom.
- Department of Biomedical Sciences, University of Birmingham, Birmingham, United Kingdom.
- School of Pharmacy, University of Birmingham, Birmingham, United Kingdom.
- School of Mathematics, University of Birmingham, Birmingham, United Kingdom.
- Birmingham Biomedical Research Centre, National Institute for Health and Care Research, University Hospitals Birmingham, Birmingham, United Kingdom.
Cite
APA
Roberts, P. A., Thomas, C. N., Bellamy Plaice, G., Roberts, J. A., Jones, M. C., Andrews, J. W., & Hill, L. J. (2025). Mathematical Models of Topically and Intravitreally Applied Ranibizumab. Investigative Ophthalmology & Visual Science. https://doi.org/10.1167/iovs.66.11.45
Vancouver
Roberts PA, Thomas CN, Bellamy Plaice G, Roberts JA, Jones MC, Andrews JW, et al. Mathematical Models of Topically and Intravitreally Applied Ranibizumab. Investigative Ophthalmology & Visual Science. 2025. doi:10.1167/iovs.66.11.45
BibTeX
@article{Roberts2025,
author = {Roberts, Paul A and Thomas, Chloe N and Bellamy Plaice, Gabriel and Roberts, James A and Jones, Marie-Christine and Andrews, James W and Hill, Lisa J},
title = {Mathematical Models of Topically and Intravitreally Applied Ranibizumab},
journal = {Investigative Ophthalmology & Visual Science},
year = {2025},
doi = {10.1167/iovs.66.11.45}
}
EUVIMED